Universal DX Announces Strategic Collaboration with Quest Diagnostics to Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States
CAMBRDIGE, Mass. and SECAUCUS, N.J., Nov. 20, 2023 /PRNewswire/ — Universal DX (“UDX”), a biotech company on a mission to transform cancer into a curable disease, today announced a strategic collaboration with Quest Diagnostics (“Quest”) (NYSE: DGX), the nation’s leading provider of diagnostic information services, designed to improve colorectal cancer screening in the United States – for which more than 110 million people may be eligible.
